Literature DB >> 23672416

Chemoresistance in ovarian cancer linked to expression of microRNAs.

P J Frederick1, H N Green, J S Huang, M E Egger, H B Frieboes, W E Grizzle, L R McNally.   

Abstract

We evaluated the differential expression of several microRNAs (miRNAs) among malignant cells in ascites and matched omental metastasis in patients with epithelial ovarian cancer (EOC). Ascites and omental tumors were collected prospectively from five patients who were undergoing primary surgical cytoreduction. Patient samples were processed and treated with carboplatin, paclitaxel and combination chemotherapy. Cell viability was evaluated and miRNA profiling was performed on both tumor cells from ascites fluid and omental cake. Quantitative real-time PCR (RT-q-PCR) and western blots were used to evaluate expressions of miRNA-21 and miRNA -214 and associated proteins. Malignant cells in ascites showed greater cell viability when treated with carboplatin compared to omental metastasis. A significant up-regulation of miRNA-21 and miRNA-214 was observed in malignant cells of ascites compared to omental metastasis; this was confirmed by both cell viability assay and RT-q-PCR. Ours is the first report that demonstrates significant up-regulation of miRNA-21 and miRNA-214 in tumor cells from ascites of patients with EOC compared to omental metastasis. This finding has important implications for intrinsic carboplatin resistance in these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23672416     DOI: 10.3109/10520295.2013.788736

Source DB:  PubMed          Journal:  Biotech Histochem        ISSN: 1052-0295            Impact factor:   1.718


  10 in total

1.  Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.

Authors:  Yilin Zhang; Shravan Kumar Sriraman; Hilary A Kenny; Ed Luther; Vladimir Torchilin; Ernst Lengyel
Journal:  Mol Cancer Ther       Date:  2016-07-27       Impact factor: 6.261

Review 2.  Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.

Authors:  Xin Yu; Heyi Zheng; Matthew Tv Chan; William Kk Wu
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

3.  Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.

Authors:  Eric A Benson; Todd C Skaar; Yunlong Liu; Kenneth P Nephew; Daniela Matei
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

Review 4.  Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.

Authors:  Duncan Ayers; Jo Vandesompele
Journal:  Genes (Basel)       Date:  2017-03-03       Impact factor: 4.096

Review 5.  The Network of Non-coding RNAs in Cancer Drug Resistance.

Authors:  Fabio Corrà; Chiara Agnoletto; Linda Minotti; Federica Baldassari; Stefano Volinia
Journal:  Front Oncol       Date:  2018-08-29       Impact factor: 6.244

Review 6.  Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs.

Authors:  Bernhard Biersack
Journal:  Noncoding RNA Res       Date:  2016-10-13

Review 7.  Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer.

Authors:  Severyn Ferneza; Markiyan Fetsych; Roman Shuliak; Halyna Makukh; Natalia Volodko; Roman Yarema; Taras Fetsych
Journal:  Ecancermedicalscience       Date:  2021-06-14

Review 8.  Involvement of non-coding RNAs in chemotherapy resistance of ovarian cancer.

Authors:  Yang Shao; Hui Li; Ran Du; Jiao Meng; Gong Yang
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207

Review 9.  Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer.

Authors:  Hongjing Zang; Jianlun Peng; Weiyuan Wang; Songqing Fan
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

Review 10.  Small Molecule Optoacoustic Contrast Agents: An Unexplored Avenue for Enhancing In Vivo Imaging.

Authors:  Matt D Laramie; Mary K Smith; Fahad Marmarchi; Lacey R McNally; Maged Henary
Journal:  Molecules       Date:  2018-10-25       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.